Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 25.65 USD 2.07% Market Closed
Market Cap: 145.4B USD
Have any thoughts about
Pfizer Inc?
Write Note

Pfizer Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pfizer Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Inc
NYSE:PFE
Cash & Cash Equivalents
$1.1B
CAGR 3-Years
-19%
CAGR 5-Years
-18%
CAGR 10-Years
-8%
Johnson & Johnson
NYSE:JNJ
Cash & Cash Equivalents
$8.2B
CAGR 3-Years
20%
CAGR 5-Years
15%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Cash & Cash Equivalents
$7.9B
CAGR 3-Years
-16%
CAGR 5-Years
-24%
CAGR 10-Years
5%
Merck & Co Inc
NYSE:MRK
Cash & Cash Equivalents
$14.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
3%
Zoetis Inc
NYSE:ZTS
Cash & Cash Equivalents
$1.7B
CAGR 3-Years
-19%
CAGR 5-Years
-1%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Cash & Cash Equivalents
$3.4B
CAGR 3-Years
-4%
CAGR 5-Years
17%
CAGR 10-Years
1%
No Stocks Found

Pfizer Inc
Glance View

Market Cap
145.4B USD
Industry
Pharmaceuticals

Pfizer Inc. is a global leader in the pharmaceutical industry, renowned for its commitment to innovative research and development that drives breakthroughs in healthcare. Founded in 1849, Pfizer has evolved into a powerhouse, particularly highlighted by its pivotal role in developing one of the first COVID-19 vaccines in collaboration with BioNTech. This achievement not only underscored the company's rapid response capabilities but also significantly boosted its revenue, showcasing its ability to pivot in times of global health crises. Investors are drawn to Pfizer not just for its historical legacy, but also for its diverse portfolio that includes treatments across various therapeutic areas such as oncology, immunology, and neurology, reflecting a balanced strategy poised for future growth. As Pfizer continues to navigate a post-pandemic world, its focus on innovation remains a cornerstone of its business strategy. With a robust pipeline of drugs in late-stage development and a strong commitment to mergers and acquisitions, Pfizer is determined to maintain market leadership while expanding its therapeutic offerings. Importantly, the company is also committed to shareholder value, consistently returning profits through dividends and share buybacks. For investors, Pfizer represents a compelling opportunity, merging stability with the potential for growth in an ever-evolving healthcare landscape, driven by advancements in science and technology.

PFE Intrinsic Value
24.05 USD
Overvaluation 6%
Intrinsic Value
Price

See Also

What is Pfizer Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.1B USD

Based on the financial report for Sep 29, 2024, Pfizer Inc's Cash & Cash Equivalents amounts to 1.1B USD.

What is Pfizer Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-8%

Over the last year, the Cash & Cash Equivalents growth was -67%. The average annual Cash & Cash Equivalents growth rates for Pfizer Inc have been -19% over the past three years , -18% over the past five years , and -8% over the past ten years .

Back to Top